JPS6340771B2 - - Google Patents
Info
- Publication number
- JPS6340771B2 JPS6340771B2 JP53044093A JP4409378A JPS6340771B2 JP S6340771 B2 JPS6340771 B2 JP S6340771B2 JP 53044093 A JP53044093 A JP 53044093A JP 4409378 A JP4409378 A JP 4409378A JP S6340771 B2 JPS6340771 B2 JP S6340771B2
- Authority
- JP
- Japan
- Prior art keywords
- milk
- casein
- whey
- months
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004080 milk Anatomy 0.000 claims description 47
- 235000013336 milk Nutrition 0.000 claims description 46
- 239000008267 milk Substances 0.000 claims description 46
- 239000012141 concentrate Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 28
- 108010046377 Whey Proteins Proteins 0.000 claims description 23
- 102000007544 Whey Proteins Human genes 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000005018 casein Substances 0.000 claims description 20
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 20
- 235000021240 caseins Nutrition 0.000 claims description 20
- 241000283690 Bos taurus Species 0.000 claims description 19
- 239000005862 Whey Substances 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 229940072221 immunoglobulins Drugs 0.000 claims description 10
- 230000006651 lactation Effects 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000005577 Gastroenteritis Diseases 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 235000021119 whey protein Nutrition 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000000356 contaminant Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 230000000369 enteropathogenic effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000011026 diafiltration Methods 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000004094 preconcentration Methods 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000012465 retentate Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 241001494479 Pecora Species 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 230000002550 fecal effect Effects 0.000 description 9
- 239000012466 permeate Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012266 salt solution Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000003022 colostrum Anatomy 0.000 description 6
- 235000021277 colostrum Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000005345 coagulation Methods 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005238 degreasing Methods 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 229940088592 immunologic factor Drugs 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001433703 Escherichia coli O111:B4 Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- QZKHGYGBYOUFGK-UHFFFAOYSA-L azocarmine B Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(S(=O)(=O)[O-])=CC=C1NC(C1=CC(=CC=C1C1=NC2=CC=CC=C22)S([O-])(=O)=O)=CC1=[N+]2C1=CC=CC=C1 QZKHGYGBYOUFGK-UHFFFAOYSA-L 0.000 description 2
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013527 degreasing agent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001200 fecal consistency Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 229910018626 Al(OH) Inorganic materials 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000028466 Escherichia coli O111 Species 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000007921 bacterial pathogenicity Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 235000020162 malted milk drink Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MHQHHBYRYFICDV-UHFFFAOYSA-M sodium;pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1CC(=O)[N-]C(=O)N1 MHQHHBYRYFICDV-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH467977A CH627079A5 (en) | 1977-04-15 | 1977-04-15 | Process for preparing a protein concentrate containing immunological factors of milk origin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53130411A JPS53130411A (en) | 1978-11-14 |
| JPS6340771B2 true JPS6340771B2 (nl) | 1988-08-12 |
Family
ID=4280585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4409378A Granted JPS53130411A (en) | 1977-04-15 | 1978-04-14 | Production of immunoglobulin containing protein concentrate |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS53130411A (nl) |
| AR (1) | AR218482A1 (nl) |
| AU (1) | AU519091B2 (nl) |
| CA (1) | CA1101333A (nl) |
| CH (1) | CH627079A5 (nl) |
| DE (1) | DE2813984A1 (nl) |
| DK (1) | DK153521C (nl) |
| ES (1) | ES468808A1 (nl) |
| FR (1) | FR2387039A1 (nl) |
| GB (1) | GB1573995A (nl) |
| GR (1) | GR64433B (nl) |
| IT (1) | IT1156193B (nl) |
| MX (1) | MX5007E (nl) |
| MY (1) | MY8100294A (nl) |
| NL (1) | NL187516C (nl) |
| OA (1) | OA05938A (nl) |
| PH (2) | PH14031A (nl) |
| SE (1) | SE448062B (nl) |
| ZA (1) | ZA781607B (nl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE448344B (sv) * | 1978-02-06 | 1987-02-16 | Stolle Res & Dev | Antikropp for behandling av reumatoid artrit samt sett att framstella denna |
| FR2460135A1 (fr) * | 1979-07-02 | 1981-01-23 | Liotet Serge | Composition a usage externe a base de colostrum |
| DE3172807D1 (en) * | 1981-04-28 | 1985-12-12 | Stolle Res & Dev | Method of obtaining an anti-inflammatory bovine milk |
| JP2561234B2 (ja) * | 1981-05-12 | 1996-12-04 | スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション | 抗炎症剤 |
| JPS58154513A (ja) * | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| NZ205392A (en) * | 1982-09-02 | 1987-03-06 | Unilever Plc | Preparation of immunoglobulins against e.coli pili |
| JPS6112629A (ja) * | 1984-06-28 | 1986-01-21 | Lion Corp | 口腔内組成物 |
| DE3432718C1 (de) * | 1984-09-06 | 1986-05-22 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen |
| US4816252A (en) * | 1985-04-15 | 1989-03-28 | Protein Technology, Inc. | Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins |
| US4834974A (en) * | 1986-01-13 | 1989-05-30 | Protein Technologies, Inc. | Immunologically active whey fraction and recovery process |
| GB8729031D0 (en) * | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
| US5258178A (en) * | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
| IE76730B1 (en) * | 1990-07-30 | 1997-11-05 | Abbott Laboraties | Method and product for the treatment of gastric disease |
| DE4026365A1 (de) * | 1990-08-21 | 1992-02-27 | Biotest Pharma Gmbh | Sterilfiltrierte kolostralmilch |
| JPH04169539A (ja) * | 1990-11-01 | 1992-06-17 | Imuno Japan:Kk | 消化器疾患治療・予防剤およびその製造方法 |
| US5645834A (en) * | 1992-08-28 | 1997-07-08 | Immuno-Dynamics, Inc. | Method and product for treating failure of passive transfer and improving milk production in bovine species |
| WO1995008562A1 (en) * | 1993-09-20 | 1995-03-30 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
| FI97269B (fi) * | 1993-10-12 | 1996-08-15 | Viable Bioproducts Ltd | Menetelmä ravintojuoman valmistamiseksi |
| ZA949789B (en) * | 1993-12-30 | 1995-10-25 | Immunotec Res Corp Ltd | Process for making undenatured whey protein concentrate |
| US5670196A (en) * | 1995-04-12 | 1997-09-23 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
| US5707678A (en) * | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
| CA2165937A1 (en) * | 1995-05-09 | 1996-11-10 | Immunotec Research Corporation Ltd. | Process for producing an undenatured whey protein concentrate |
| AUPN642795A0 (en) * | 1995-11-08 | 1995-11-30 | Northfield Laboratories Pty Ltd | Dairy compositions and methods of preparing same |
| US5772999A (en) * | 1996-07-30 | 1998-06-30 | Dcv Biologics, L.P. | Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals |
| EP0990001B1 (en) * | 1997-05-29 | 2006-05-10 | Agresearch Limited | Processes for production of immunoglobulin a in milk |
| IE970541A1 (en) † | 1997-07-25 | 1999-01-27 | Michael Anthony Folan | Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity |
| FI110752B (fi) | 1999-05-25 | 2003-03-31 | Novatreat Oy | Menetelmä ternimaidon käsittelemiseksi |
| SE0003045D0 (sv) * | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| DK1435786T3 (da) | 2001-09-17 | 2011-10-03 | Lilly Co Eli | Pesticide formuleringer |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| ATE361101T1 (de) | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
| NL1033696C2 (nl) * | 2007-04-16 | 2008-10-20 | Friesland Brands Bv | Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan. |
| WO2009092383A2 (en) | 2008-01-22 | 2009-07-30 | Multimerics Aps | Products and methods to prevent infection |
| KR101645957B1 (ko) * | 2008-05-15 | 2016-08-05 | 더블유. 헬스 엘.피. | 분비 면역글로블린이 풍부한 우유 분획 제조방법 |
| CA2760096C (en) | 2009-04-27 | 2018-10-30 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder. |
| US9943597B2 (en) | 2010-08-17 | 2018-04-17 | Immuron Limited | Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| US10278404B2 (en) * | 2012-09-11 | 2019-05-07 | Al-Urdonia Lemudaddat Al-Ajsam Co | Immunized camel milk-based composition for the treatment or prevention of gastrointestinal infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE546837A (nl) * | ||||
| DE1022356B (de) * | 1955-04-07 | 1958-01-09 | Berry Campbell | Verfahren zur Herstellung eines spezifischen Schutzstoffes gegen ein Antigen |
| DK87610C (da) * | 1955-04-07 | 1959-07-27 | Berry Campbell | Fremgangsmåde til fremstilling af specifikke beskyttelsesstoffer mod antigene stoffer. |
| FR1599671A (nl) * | 1966-06-27 | 1970-07-20 | ||
| GB1211876A (en) * | 1967-11-23 | 1970-11-11 | Twyford Lab Ltd | Improvements in and relating to prophylactic and therapeutic preparations |
| NL7011786A (nl) * | 1969-09-24 | 1971-03-26 | ||
| US3930039A (en) * | 1971-07-30 | 1975-12-30 | Molkerei J A Meggle Milchindus | Method of preparing a protein concentrate from whey |
| BE788120A (fr) * | 1971-09-01 | 1973-02-28 | Coca Cola Co | Traitement des proteines du petit-lait |
| US3911108A (en) * | 1973-02-14 | 1975-10-07 | Diamond Shamrock Corp | Process of producing bovine milk products containing specific antibodies |
-
1977
- 1977-04-15 CH CH467977A patent/CH627079A5/fr not_active IP Right Cessation
-
1978
- 1978-03-20 ZA ZA00781607A patent/ZA781607B/xx unknown
- 1978-03-21 GB GB11106/78A patent/GB1573995A/en not_active Expired
- 1978-03-22 DK DK131078A patent/DK153521C/da not_active IP Right Cessation
- 1978-03-24 FR FR7808705A patent/FR2387039A1/fr active Granted
- 1978-03-31 DE DE19782813984 patent/DE2813984A1/de active Granted
- 1978-04-03 MX MX786992U patent/MX5007E/es unknown
- 1978-04-06 AR AR271715A patent/AR218482A1/es active
- 1978-04-10 AU AU34903/78A patent/AU519091B2/en not_active Expired
- 1978-04-10 CA CA300,770A patent/CA1101333A/fr not_active Expired
- 1978-04-11 PH PH20991A patent/PH14031A/en unknown
- 1978-04-13 SE SE7804190A patent/SE448062B/sv not_active IP Right Cessation
- 1978-04-14 OA OA56468A patent/OA05938A/xx unknown
- 1978-04-14 ES ES468808A patent/ES468808A1/es not_active Expired
- 1978-04-14 NL NLAANVRAGE7804015,A patent/NL187516C/nl not_active IP Right Cessation
- 1978-04-14 JP JP4409378A patent/JPS53130411A/ja active Granted
- 1978-04-14 GR GR55978A patent/GR64433B/el unknown
- 1978-04-14 IT IT48896/78A patent/IT1156193B/it active
-
1979
- 1979-01-29 PH PH22133A patent/PH17782A/en unknown
-
1981
- 1981-12-30 MY MY294/81A patent/MY8100294A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2387039B1 (nl) | 1981-07-24 |
| GB1573995A (en) | 1980-09-03 |
| CA1101333A (fr) | 1981-05-19 |
| JPS53130411A (en) | 1978-11-14 |
| GR64433B (en) | 1980-03-21 |
| CH627079A5 (en) | 1981-12-31 |
| AU519091B2 (en) | 1981-11-05 |
| NL7804015A (nl) | 1978-10-17 |
| MX5007E (es) | 1983-02-14 |
| PH14031A (en) | 1980-12-12 |
| IT7848896A0 (it) | 1978-04-14 |
| AR218482A1 (es) | 1980-06-13 |
| IT1156193B (it) | 1987-01-28 |
| DK131078A (da) | 1978-10-16 |
| ZA781607B (en) | 1979-03-28 |
| PH17782A (en) | 1984-12-11 |
| NL187516C (nl) | 1991-11-01 |
| MY8100294A (en) | 1981-12-31 |
| DK153521C (da) | 1988-12-05 |
| NL187516B (nl) | 1991-06-03 |
| OA05938A (fr) | 1981-06-30 |
| SE448062B (sv) | 1987-01-19 |
| FR2387039A1 (fr) | 1978-11-10 |
| DK153521B (da) | 1988-07-25 |
| DE2813984A1 (de) | 1978-10-26 |
| ES468808A1 (es) | 1978-12-01 |
| SE7804190L (sv) | 1978-10-16 |
| DE2813984C2 (nl) | 1987-11-26 |
| AU3490378A (en) | 1979-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6340771B2 (nl) | ||
| JP5762951B2 (ja) | 分泌性免疫グロブリンの豊富な乳画分の製造方法 | |
| US5707678A (en) | Method for microfiltration of milk or colostral whey | |
| US4784850A (en) | Process for preparing antibodies against E. Coli K-99 antigen from bovine milk | |
| JPH01502110A (ja) | 免疫学的に活性なホエ−分画及び回収方法 | |
| US4051235A (en) | Method of preparing bovine colostrum for use in treating livestock | |
| US5066491A (en) | Method of disease treatment utilizing an immunologically active whey fraction | |
| JP3616955B2 (ja) | 初乳を処理する方法 | |
| US5670196A (en) | Method for microfiltration of milk or colostral whey | |
| JP2002501526A (ja) | 乳汁における免疫グロブリンａの生成方法 | |
| RU2727504C1 (ru) | Способ двухстадийного мембранного получения гипоаллергенного продукта на основе лактоферрина, обогащенного иммуноглобулинами, для профилактического диетического питания | |
| US4971794A (en) | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili | |
| EP0102831B1 (en) | Production of antibodies | |
| Ratner et al. | Anaphylactogenic properties of milk: Immunochemistry of the purified proteins and antigenic changes resulting from heat and acidification | |
| CN1787829B (zh) | 抗轮状病毒感染的组合物及制备该组合物的方法 | |
| US5747031A (en) | Process for isolating immunoglobulins in whey | |
| EP3454673B1 (en) | Whey preparation for improving brain development | |
| CN101014253A (zh) | 人乳强化剂及其生产方法 | |
| US5198213A (en) | Method of disease treatment utilizing an immunologically whey fraction | |
| WO2011064114A1 (en) | Mixture of biological factors isolated from colostrum | |
| Elkot | Characterization and healthier properties of whey proteins of camel milk: A review | |
| US7547770B2 (en) | Colostral fractionation process | |
| JPH04275232A (ja) | 胃炎，胃または十二指腸潰瘍予防食品 | |
| WO1992002538A1 (en) | Product and method for transfer of colostrum-derived disease preventing constituents across the gastrointestinal tract | |
| RU2062109C1 (ru) | Способ получения иммунного препарата |